乌苯美司联合MPT治疗不愿静脉化疗多发性骨髓瘤的疗效观察  

Efficacy of ubenimex combined with MPT on multiple myeloma patients who are unwilling to re-ceive intravenous chemotherapy

作　　者：秦福丽[1] 郭志强[1] 石丽芳[1] 李小雨[1] 邓梅[1] 宋君君[1] 刘艳艳[1] 

机构地区：[1]郑州大学附属郑州市中心医院血液内科,450007

出　　处：《中国实用医刊》2013年第23期106-107,共2页Chinese Journal of Practical Medicine

摘　　要：目的探讨乌苯关司对中老年不愿静脉化疗的多发性骨髓瘤患者的疗效和免疫功能的影响。方法将患者随机分为两组，对照组应用MPT方案，治疗组应用MPT和乌苯关司片，2个周期后评价疗效和T细胞亚群。结果两组CD4^＋T细胞比例治疗前均较治疗后低；CD8^＋T细胞比例治疗前均较治疗后高，差异均有统计学意义。两组之间治疗前后比较差异无统计学意义。治疗组有效率高于对照组，差异有统计学意义。结论乌苯美司联合化疗可提高化疗有效率。Objective To investigate the effect and immune function of ubenimex in the treatment of middle-aged and aged patients with multiple myeloma who were unwilling to receive intravenous chemo-therapy. Methods Patients were divided into two groups randomly, control group applied MPT scheme, treatment group applied MPT and ubenimex. Efficacy and T cell Results Both group of CD4^＋ T cell percentage were lower after subgroup were evaluated after two cycles. treatment than before treatment, CD8^＋ T cell percentage were higher after treatment than before treatment, the differences were statistically signifi-cant. There was no significant difference between the two groups before and after treatment. The effective rate of treatment group was higher than that of control group, the difference was statistically significant. Conclusions Ubenimex combined with chemotherapy can improve the treatment efficiency.

关 键 词：乌苯美司 中老年 多发性骨髓瘤 免疫功能 

分 类 号：R733.3[医药卫生—肿瘤]